title: How should we advise patients about the contraceptive patch, given the FDA warning?
authors.affiliation: Women's Health Center at The Gault Women's Health and Breast Pavilion, Department of General Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA. thackeh@ccf.org
authors.forename: Holly L
authors.initials: HL
authors.lastname: Thacker
authors.forename: Tommaso
authors.initials: T
authors.lastname: Falcone
authors.forename: Ashish
authors.initials: A
authors.lastname: Atreja
authors.forename: Anil
authors.initials: A
authors.lastname: Jain
authors.forename: C Martin
authors.initials: CM
authors.lastname: Harris
mesh_terms: D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003376:Counseling; D004338:Drug Combinations; D004363:Drug Utilization; D005003:Ethisterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D009644:Norgestrel / Q000009:adverse effects / Q000031:analogs & derivatives*; D010091:Oximes / Q000009:adverse effects; D010817:Physician-Patient Relations; D010818:Practice Patterns, Physicians'; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration; D020246:Venous Thrombosis / Q000139:chemically induced
chemical_list: D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D010091:Oximes; D009644:Norgestrel; D005003:Ethisterone; C449219:norelgestromin